Hormone Receptor Positive and HER2+ Breast Cancer

Transcription

1 Hormone Receptor Positive and HER2+ Breast Cancer Jennifer L.A. Armstrong, MD Paoli Hematology-Oncology Associates

2 Introduction Breast cancer update just for you Hormone receptor positive disease HER2+ disease Definitions (what you need to know ) Treatment (how it s different in each)

3 Definitions How do we talk about breast cancer from a medical perspective? How do we classify breast cancer? What are the different types? Why is this important? Because they behave differently And may be treated differently

4 Breast Cancer Histology Adenocarcinoma (gland forming) Ductal more common than Lobular Tubular, Mucinous, Anaplastic Invasive vs non-invasive = in situ Other: lymphoma, sarcoma, melanoma

5 Breast Cancer Pathology Tumor size Grade of differentiation Low = Grade I = well differentiated Intermediate = Grade II High = Grade III = poorly differentiated Lymph node involvement ( of )

6 Pathology, cont d Immunohistochemical staining for ER/PR Estrogen receptor (ER) Progesterone receptor (PR) If either > 5-10% then considered hormone receptor positive Staining for HER2

7 Pathology, cont d IHC testing for HER2/neu expression 0 and 1+ = negative 2+ = indeterminate test by FISH 3+ = positive FISH testing for HER2 expression Negative, positive, or indeterminate

8 Sub-groups of breast cancer Hormone receptor positive (HRP) Hormone receptor negative (HRN) HER2 positive (HER2+) Triple negative neither HER2+ nor HRP

9 Staging TNM system Tumor size (in centimeters) Nodal status Negative ( lymph node negative ) Positive: 1-4 LN vs >4 LN Metastatic disease Spread beyond the breast and draining lymph nodes

10 Staging

11 Staging

12

13 Staging TNM Stage 0 = carcinoma in situ (DCIS or LCIS) Stage 1 = tumors under 2cm Stage 2 = small tumors with involved nodes, or larger tumors without nodes Stage 3 = large tumors and involved nodes Stage 4 = metastatic disease

14 Limits of Staging Doesn t take into account (currently) Hormone receptor status HER2neu expression Menopausal status But these impact treatment decisions!

15 Clinical Staging DCIS/LCIS (Stage 0) Tumors < 1cm versus > 2cm Lymph node involvement Hormone receptor status HER2neu expression Menopausal status

16 Clinical Staging > Impacts Treatment DCIS/LCIS (Stage 0) -> not cancer Tumors < 1cm versus > 2cm -> chemo? Lymph node involvement -> (chemo) Hormone receptor status -> anti-estrogen tx HER2neu expression -> Herceptin Menopausal status -> (subtleties)

17 Adjuvant vs Metastatic Adjuvant After surgery or other treatment with curative intent (such as chemotherapy) Neo-adjuvant Before surgery or other treatment with curative intent (such as chemotherapy) Metastatic Spread beyond

18 Adjuvant vs Metastatic, cont d Adjuvant All treatment with curative intent Used in patients with Stage 1-3 disease Neo-adjuvant Also with curative intent Metastatic = Stage 4 Treatment is palliative, not curative

19 Treatment Why do different people get different treatment for breast cancer? Which treatment to pursue impacted by Stage (TNM 0, 1 4) Type (HRP, HER2 expression) Other factors that impact risk of recurrence (such as menopause)

20 Treatment Treatment in the Adjuvant setting Hormone Receptor Positive disease HER2+ disease Treatment in the Metastatic setting Hormone Receptor Positive disease HER2+ disease

21

22 Treatment in Adjuvant Setting For patients with stage (0), 1-3 Treatment with curative intent Multimodality Different for patients with HER2+ HRP = hormone receptor positive

23 Treatment Multidisciplinary approach Surgery Radiation Systemic therapy Anti-estrogen if HRP Chemotherapy Who needs which treatment?

24

25 Treatment Local can be curative by itself Surgery Radiation Systemic can be added to increase cure Chemotherapy *Anti-HER2 directed therapy (if HER2+) Anti-estrogen therapy (if HRP)

26 Adjuvant Treatment - Systemic Anti-estrogen therapy For anyone with hormone receptor positive (HRP) disease Tamoxifen in pre- or post-menopausal Aromatase Inhibitors only in post-mp (evolving data for use in pre-mp women with ovarian shut down)

27 Anti-estrogen therapy - Updates For post menopausal women Aromatase Inhibitors with persuasive data over Tamoxifen for 5 years Anastrozole = Arimidex Letrozole = Femara Exemestane = Aromasin Now data to support 10 years

28 Anti-estrogen therapy TAM vs AI Side effects (all): Hot flashes, night sweats Weight gain, depression Vaginal dryness and sexual dysfnc Low white count Elevated liver enzymes?cataracts,?lipid abnl (esp with Tam?)

29 TAM vs. AI, (cont d) TAM AI 2-4% risk of VTE 1-2% 1-2% risk uterine ca --- (protects) osteoporosis (?worsens) <1% arthralgias 30-70% (traditional) (more effective)

30 Anti-estrogen therapy, (cont d) Recommendations Yearly Ophtho and GYN visits if on TAM Baseline DEXA scan if on AI Repeat (every 2 years) if DEXA abnormal with low threshold to use bisphosphonates Fosamax or Actonel (pills) Zometa IV (annually) or Prolia SQ (2x/yr)

31 Adjuvant Treatment - Systemic Chemotherapy Who needs it?

32 Adjuvant Chemotherapy Based on risk of recurrence of cancer Tumor size, nodal status ER/PR/HER2 Grade, lymphovascular invasion Risks vs benefits Age and performance status of patient Menopausal status

33 Calculating Risk Norton rule of thumb Uses only size and lymph node status Adjuvant! On-line tool with multiple variables Oncotype Assay and Mammaprint Genomic assays

34 Calculating Risk, (cont d) Adjuvant! Computerized prognostic model for estimating risk of recurrence (and likely benefit from adjuvant therapy) From SEER database (Surveillance, Epidemiology and End Results program of NCI) Ravdin, et al, JCO 2001

35 Calculating Risk, (cont d) Oncotype DX assay Originally for LN-neg, HRP, post-menopausal women Genomic assay performed on tissue itself Used to see if chemotherapy likely to beneficial Categorizes into low, intermediate, or high risk Low risk -> derive little benefit from chemotherapy High risk -> derive significant benefit from chemo Intermediate risk -> test not helpful Fisher, et al, NEJM 2004

36

37 Treatment - Adjuvant Adjuvant chemotherapy recommended if risk of recurrence > 10% Norton rule Adjuvant! Online High risk features Triple negative HER2+

38 Treatment Adjuvant, (cont d) If post-menopausal, HRP, HER2-neg, lymph node negative Offer chemo only if >2cm (or more) If pre-menopausal, HRP, HER2-neg, lymph node negative Offer chemo if >2cm May also offer if >1cm and high risk

39 Treatment Adjuvant, (cont d) If post-mp, HRP, HER2-neg, LN neg Offer chemo only if >2cm Or if Oncotype HIGH RISK at any size If pre-mp, HRP, HER2-neg, LN neg Offer chemo if >2cm May also offer if >1cm and high risk

40 Treatment Adjuvant, (cont d) If HER2+, offer chemo if > 0.5cm If triple negative, offer chemo if > 0.5cm If lymph node positive, offer chemo Oncotype now validated here Now can spare some women with even lymph positive disease chemotherapy, if low risk Oncotype score

41 Adjuvant Chemotherapy Which regimen? Not different based on hormone receptor status (HRP vs HRN) Although whether to pursue chemo at all may impact decision for chemo Very different if HER2+

42 Adjuvant Chemotherapy - for NON-HER2 overexpressing AC = Adriamycin (Doxorubicin) + Cytoxan (Cyclophosphamide) TC = Taxotere (Docetaxel) + CTXN ddac/t = dose dense AC followed by Taxol (Paclitaxel) TAC (toxic), ECF/FEC/FAC (Europe), CMF (elderly), many others

43 Adjuvant Chemo, (cont d) AC TC TC shown to be non-inferior to AC in lymph node pos and neg pts But AC inferior to ddac/t in LN+ pts TC avoids cardiotoxicity of anthracycline ddac/t OS adv in high risk pts Need to follow MUGA/echo -> cardio-onc Jones et al, JCO 2009

44 Adjuvant Chemo - in triple neg Triple negative = ER/PR/HER2 negative Any of the above regimens +/- Addition of Carboplatin Phase II data promising Await Phase III (large cooperative trial now)

45 Adjuvant Chemo - in HER2+ AC/TH addition of Trastuzumab (Herceptin) AC every 2 weeks x 4 T+H weekly x 12 (or every 2 weeks x 4) Followed by completion of 1 year Trastuzumab In neo-adjuvant setting THP = Taxotere, Herceptin, Perjeta TCHP = all above with Carboplatin

46 Neo-adjuvant chemotherapy Given before curative intent (surgery) To downstage Allow surgical resection Improve ability to get clean margins Especially inflammatory breast cancer Has never been shown to improve overall survival

47 Targeting the HER2 receptor HER2/neu is an EGFR (epidermal growth factor receptor) Constitutively turned ON => tumor growth Anti-HER2 directed therapy targets that very growth factor => to turn it off Trastuzumab (Herceptin) Pertuzumab (Perjeta)

48 Targeting the HER2 receptor Combination with dual anti-her targets Trastuzumab + Pertuzumab (synergistic) Approved in the metastatic setting Approved in the neoadjuvant setting Being studied in the adjuvant setting

49 Adjuvant Treatment - timing Establish diagnosis of breast ca (biopsy) (Neo-adjuvant treatment) Definitive surgery (Adjuvant chemotherapy) (Adjuvant radiation therapy) (Anti-estrogen therapy)

50 Different presentations Not everyone is early stage at presentation Some patients diagnosed with metastatic disease at presentation Some patients go through all of above, and then develop metastatic disease despite having completed adjuvant treatment

51 Treatment in Metastatic Setting Palliative (not curative) Goal to improve quantity and quality life Live longer Feel better Paradigm shift Less is more reduce toxicity without reducing efficacy

52 Sequential, single agent therapy in the metastatic setting More isn t always better Use as few agents for as long as possible No studies to show combination therapy in metatstatic setting has improved survival over sequential, single agent therapy Except in HER2 overexpressing disease Where combo of dual anti-her2 synergistic Or if need quick response

53 Treatment Treatment in the Adjuvant setting Hormone Receptor Positive disease HER2+ disease Treatment in the Metastatic setting Hormone Receptor Positive disease HER2+ disease

54 Treatment - Metastatic Extent of tumor burden Impending visceral crisis Symptomatic Hormone receptor positive HER2 positive

55 Treatment Metastatic, (cont d) If HRP, HER2-neg, and stable -> anti-estrogen tx If HER2-pos and needs chemo -> regimen containing anti-her2 targeted therapy THP or TCHP If HER2-neg and needs chemo -> single agent

56 Treatment Metastatic, (cont d) If HRP, HER2-neg, and stable -> anti-estrogen tx Tamoxifen (pre or post menopausal) Aromatase Inhibitor With ovarian shut down in pre-menopausal Choice of agents / sequence Anastrazole = Letrozole?Exemestane different Fulvestrant (Faslodex) intramuscularly

57 Treatment Metastatic, (cont d) If HRP, HER2-neg, and stable -> anti-estrogen tx Choice of agents / sequence Combinations Letrozole + Palbociclib (Ibrance) (CDK4 and CDK6 inhibitor) Exemestane + Everolimus (Afinitor) (mtor inhibitor)

58 Treatment Metastatic, (cont d) If HRP, HER2-neg, and stable -> anti-estrogen tx If HER2-pos and needs chemo -> regimen containing anti-her2 targeted therapy Dual anti-her2 targeted therapy considered standard first line (if tolerated) THP or TCHP TCHP = Taxotere (Docetaxel) + Carboplatin + Herceptin (Trastuzumab) + Perjeta (Pertuzumab)

59 Treatment Metastatic, (cont d) THP or TCHP often followed by maintenance anti-her2 therapy Dual if tolerated Single agent otherwise Continue indefinitely So long as well tolerated Remain efficacious

60 Treatment Metastatic, (cont d) Most common dose limiting side effects Fatigue (Myelosuppression from the chemo) Cardio-toxicity NOT coronary artery disease or MI Rather pump function of heart (cardiomyopathy)

61

62 Cardiotoxicity Anthracyclines Doxorubicin (Adriamycin) Cardio-protectants (Zinecard) Anti-HER2 targeting (more reversible) Trastuzumab (Herceptin) Pertuzumab (Perjeta) (Synergistic cardiotoxicity NOT seen yet in combination)

63 Treatment Metastatic HER2+ First line If also HRP then anti-estrogen therapy reasonable If combination chemotherapy indicated then THP or TCHP (with anti-her2 maintenance) Multiple options after that

64 Treatment Metastatic HER2+ Second line Ado-trastuzumab emtansine (Kadcyla) Anti-HER2 directed conjugated to chemo (same risk of cardiotoxicity) Lapatinib (Tykerb) + Capecitabine (Xeloda) All oral (pills) Crosses the blood brain barrier Rash and diarrhea can be dose limiting

65 Treatment Metastatic HER2+ Third line Whichever one not previously seen: Ado-trastuzumab emtansine (Kadcyla) Lapatinib (Tykerb) + Capecitabine (Xeloda) Non-HER2 targeted therapy (Same chemotherapy agents for NON-HER2 overexpressing patients) Single agent, sequential therapy

66

67 Summary Breast Cancer Histology, Pathology, Classification, Staining, and Sub-types Staging Clinical factors that impact decision making

68 Summary Treatment in the Adjuvant setting Hormone Receptor Positive disease HER2+ disease Treatment in the Metastatic setting Hormone Receptor Positive disease HER2+ disease

69